Do you meet the criteria for lung cancer screening??
The National Comprehensive Cancer Network (NCCN) recommends annual low-dose CT (LDCT) screening (category 1) for individuals classified as higher risk based on the following criteria:
- Age ≥50 years, AND
- ≥20 pack-year history of smoking cigarettes (category 1), or ≥20-year history of smoking cigarettes (category 2B)
Notably, the NCCN does not impose a quit-year restriction — individuals who quit smoking more than 15 years ago remain eligible if they meet the age and smoking history criteria.
The NCCN Lung Cancer Screening algorithm is shown below:
Risk Assessment should include evaluation of:
- Cigarette smoking history
- Radon exposure (documented sustained and substantially elevated exposure increases risk)
- Occupational exposure (arsenic, asbestos, beryllium, cadmium, chromium, coal smoke, diesel fumes, nickel, silica, soot, uranium)
- Cancer history (survivors of lymphoma, breast cancer, head and neck cancer, or other smoking-related cancers, or those who received chest radiation)
- Family history of lung cancer in first-degree relatives
- Disease history (COPD or pulmonary fibrosis)
- Second-hand smoke exposure (not independently sufficient for screening eligibility)
- Risk calculators (PLCOm2012 or Tammemägi model) to enhance risk determination
Individual NOT eligible for lung cancer screening include those with:
- Although randomized trial evidence supports screening up to age 77, screening beyond age 77 may be considered if functional status and comorbidity allow curative-intent therapy
- Black and African American individuals with less cigarette smoking exposure have a similar risk for lung cancer as white individuals with more exposure — this should be factored into shared decision-making
- Curative-intent treatment includes surgery, SABR/SBRT, and ablative image-guided thermal ablation; advanced age or severe COPD alone do not preclude screening eligibility if SABR or IGTA remains an option
- A discussion of benefits and risks is recommended before initiating screening
Important consideration:
- Organ engineering – lab-grown hearts, lungs, and kidneys.
- Advanced tissue models – “lungs-on-a-chip” and other microphysiological systems for drug testing.
- Novel delivery systems – stimuli-responsive biomaterials for targeted drug delivery.
- Microrobots and nanotechnology – for targeted tissue repair, such as spinal cord injury regeneration.
Comparison of Major Guideline Eligibility Criteria
The USPSTF (2021) recommends annual LDCT screening for adults aged 50–80 years with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years (B recommendation). Screening should be discontinued once a person has not smoked for 15 years or develops a health problem substantially limiting life expectancy or ability to undergo curative surgery. This was a significant expansion from the 2013 criteria (age 55–80, ≥30 pack-years).
The American Cancer Society (2023) similarly recommends annual LDCT for ages 50–80 with ≥20 pack-years, and notably removed the quit-year requirement, aligning more closely with the NCCN approach.
The American College of Chest Physicians (CHEST) offers a tiered approach: a strong recommendation for ages 55–77 with ≥30 pack-years, and a conditional recommendation for ages 50–80 with ≥20 pack-years who currently smoke or quit within 15 years. CHEST also suggests screening for individuals projected to have high net benefit based on validated risk prediction calculators.
Evidence for Mortality Benefit
The two landmark trials — the NLST and NELSON — demonstrated significant reductions in lung cancer mortality. The NLST showed a 15% reduction (IRR 0.85; NNS 323 over 6.5 years) comparing LDCT to chest radiography, while the NELSON trial demonstrated a 25% reduction (IRR 0.75; NNS 130 over 10 years) comparing LDCT to no screening. A Cochrane meta-analysis of 8 trials (91,122 participants) confirmed a 21% reduction in lung cancer mortality (RR 0.79) and a 5% reduction in all-cause mortality (RR 0.95) with LDCT screening.
Harms of Screening
Key harms include false-positive results (abnormalities found in ~1 in 7 screened individuals, with ~90% being non-cancerous), leading to additional imaging in nearly one-third of screened patients and invasive procedures in ~2.8%. In the NLST, false-positive results led to 17 invasive procedures per 1,000 persons screened (NNH 59), with fewer than 1 major complication per 1,000. Overdiagnosis estimates vary widely (0%–67%), and incidental findings are common (4.4%–40.7% of screened individuals). Radiation exposure from repeated LDCT carries a very small theoretical risk of radiation-induced cancer.
If you meet the criteria for lung cancer screening and would like to pursue the screening low dose CT Scan of the chest, please call our office at (707) 938-1255 to set up an appointment with Dr. Guy.